olivLaw · US equity research
Starling Oncology, Inc. STLN
Services-Offices & Clinics of Doctors of Medicine · SIC 8011 · Vertical: Services-Offices & Clinics of Doctors of Medicine (SIC 8011)
Starling Oncology (formerly The Oncology Institute) runs community oncology clinics but increasingly earns its revenue from value-based contracts, in which it takes on the cost risk of care for patient populations. Revenue rose 34.6% in the second quarter of 2026, and the company raised its 2026 guidance, which makes its model closely watched by investors.
At the close of 04 Nov 2026, Starling Oncology, Inc. (STLN) stock was 6.94 USD (+9.46% on the day), with market capitalisation 707.3 m USD, beta 1.72, 52-week range 2.39–7.05 USD. Latest reported quarter (Q2 2026): revenue of 161.3 m USD (+34.6% YoY), net income of -9.8 m USD, diluted EPS -0.08 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 56.8
- strong (55–70)
- Bollinger (20, 2)
- 6.15 – 7.05
- in the upper half of the band · %B 0.87 · band width 13.6%
- SMA 50 / 200
- 6.48 / 4.74
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 0.03 / 0.04
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +10.2% | −1.1% | +11.3 pp | — |
| 3 months | +38.0% | −0.5% | +38.4 pp | — |
| 6 months | +82.6% | +4.4% | +78.2 pp | — |
| Year to date | +94.9% | +12.3% | +82.6 pp | — |
| 1 year | +63.7% | +13.5% | +50.1 pp | −18.7% |
| 3 years | +243.6% | +76.4% | +167.2 pp | −57.3% |
| 5 years | −30.5% | +63.7% | −94.1 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 99.9 m | 100.3 m | 104.4 m | 119.8 m | 136.6 m | 142.0 m | 147.4 m | 161.3 m |
| SG&A | 26.6 m | 24.9 m | 25.4 m | 26.9 m | 25.3 m | 28.0 m | 28.2 m | 29.9 m |
| Operating income | -13.9 m | -11.9 m | -9.9 m | -11.2 m | -8.1 m | -6.9 m | -6.5 m | -4.6 m |
| Depreciation & amortisation | 1.6 m | 1.7 m | 1.8 m | 1.8 m | 1.7 m | 1.6 m | 1.6 m | 1.8 m |
| Interest expense | 2.2 m | 1.2 m | 5.6 m | 1.9 m | 1.9 m | 1.9 m | 1.9 m | 1.9 m |
| Pre-tax income | -16.1 m | -13.2 m | -19.6 m | -17.1 m | -16.5 m | -7.5 m | -2.5 m | -9.8 m |
| Income tax | 0 | 0 | 0 | -131.0 k | 0 | 0 | 0 | 0 |
| Net income | -16.1 m | -13.2 m | -19.6 m | -17.0 m | -16.5 m | -7.5 m | -2.5 m | -9.8 m |
| Diluted EPS | -0.18 | -0.17 ≈ | -0.21 | -0.15 | -0.14 | -0.07 ≈ | -0.02 | -0.08 |
| Operating cash flow | 819.0 k ≈ | 4.0 m | -5.0 m | -10.2 m ≈ | -12.6 m ≈ | 3.2 m | -2.2 m | 11.9 m ≈ |
| Capex | -402.0 k ≈ | 1.8 m | 328.0 k | 1.2 m ≈ | 604.0 k ≈ | 1.1 m | 1.0 m | 908.0 k ≈ |
| Share repurchases | 0 ≈ | 0 | — | — | — | — | — | — |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 187.5 m | 203.0 m | 252.5 m | 324.2 m | 393.4 m | 502.7 m |
| Revenue YoY | unavailable | +8.3% | +24.4% | +28.4% | +21.3% | +27.8% |
| Net income | -14.3 m | -10.9 m | 152.0 k | -83.1 m | -64.7 m | -60.6 m |
| Net income YoY | unavailable | unavailable | unavailable | −54,750.0% | unavailable | unavailable |
| Diluted EPS | -0.24 | -0.16 | -0.21 | -0.92 | -0.71 | -0.54 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -7.6% | -5.4% | 0.1% | -25.6% | -16.4% | -12.1% |
| Free cash flow | -686.0 k | -35.5 m | -67.3 m | -40.9 m | -30.3 m | -27.8 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 33.6 m USD
- Financial debt
- 77.4 m USD
- Net debt
- 43.8 m USD
- Equity
- -15.7 m USD
- Total assets
- 164.7 m USD
- Debt / equity
- unavailable
- Current ratio
- 1.59x
- ROE
- unavailable
- ROA
- -35.9%
- FCF margin
- -5.5%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 187.5 m | 203.0 m | 252.5 m | 324.2 m | 393.4 m | 502.7 m | SEC (XBRL)· 12 Mar 2026verified |
| SG&A | 41.9 m | 83.4 m | 119.7 m | 113.9 m | 107.8 m | 105.6 m | SEC (XBRL)· 12 Mar 2026verified |
| Operating income | -8.2 m | -45.9 m | -82.0 m | -77.0 m | -60.1 m | -36.1 m | SEC (XBRL)· 12 Mar 2026verified |
| Depreciation & amortisation | 3.2 m | 3.3 m | 4.4 m | 5.9 m | 6.3 m | 6.9 m | SEC (XBRL)· 12 Mar 2026verified |
| EBITDA | -5.0 m ≈ | -42.5 m ≈ | -77.5 m ≈ | -71.1 m ≈ | -53.8 m ≈ | -29.1 m ≈ | SEC (XBRL)· 12 Mar 2026derived |
| Interest expense | 347.0 k | 320.0 k | — | 6.8 m | 7.5 m | 11.3 m | SEC (XBRL)· 12 Mar 2026verified |
| Pre-tax income | -14.8 m | -11.6 m | -91.0 k | -83.1 m | -64.7 m | -60.7 m | SEC (XBRL)· 12 Mar 2026verified |
| Income tax | -493.0 k | -671.0 k | -243.0 k | -36.0 k | 0 | -131.0 k | SEC (XBRL)· 12 Mar 2026verified |
| Net income | -14.3 m | -10.9 m | 152.0 k | -83.1 m | -64.7 m | -60.6 m | SEC (XBRL)· 12 Mar 2026verified |
| Diluted EPS | -0.24 | -0.16 | -0.21 | -0.92 | -0.71 | -0.54 | SEC (XBRL)· 12 Mar 2026verified |
| Weighted average diluted shares | 59.1 m | 66.2 m | 80.6 m | 73.7 m | 75.0 m | 92.4 m | SEC (XBRL)· 12 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 900.0 k | 115.2 m | 14.0 m | 33.5 m | 49.7 m | 33.6 m | SEC (XBRL)· 12 Mar 2026verified |
| Receivables | 17.1 m | 20.0 m | 39.8 m | 42.4 m | 48.3 m | 59.0 m | SEC (XBRL)· 12 Mar 2026verified |
| Inventories | 4.4 m | 6.4 m | 9.3 m | 13.7 m | 10.0 m | 16.9 m | SEC (XBRL)· 12 Mar 2026verified |
| Current assets | 29.7 m | 154.1 m | 130.4 m | 143.5 m | 112.4 m | 112.7 m | SEC (XBRL)· 12 Mar 2026verified |
| Property, plant & equipment, net | 2.1 m | 4.2 m | 8.5 m | 10.9 m | 11.9 m | 10.7 m | SEC (XBRL)· 12 Mar 2026verified |
| Goodwill | 14.2 m | 26.6 m | 21.4 m | 7.2 m | 7.2 m | 7.2 m | SEC (XBRL)· 12 Mar 2026verified |
| Intangibles (excl. goodwill) | 19.5 m | 18.2 m | 18.0 m | 17.9 m | 14.8 m | 11.0 m | SEC (XBRL)· 12 Mar 2026verified |
| Total assets | 65.7 m | 203.4 m | 261.7 m | 209.2 m | 172.7 m | 164.7 m | SEC (XBRL)· 12 Mar 2026verified |
| Accounts payable | 12.6 m | 15.6 m | 9.4 m | 14.4 m | 24.3 m | 43.2 m | SEC (XBRL)· 12 Mar 2026verified |
| Short-term debt | 5.4 m | 183.0 k | 0 | — | — | — | SEC (XBRL)· 16 Mar 2023verified |
| Long-term debt | 6.6 m | 0 | 80.6 m | 86.8 m | 93.1 m | 77.4 m | SEC (XBRL)· 12 Mar 2026verified |
| Current liabilities | 28.6 m | 29.8 m | 29.7 m | 34.8 m | 52.2 m | 71.0 m | SEC (XBRL)· 12 Mar 2026verified |
| Total liabilities | 37.6 m | 99.3 m | 138.5 m | 152.2 m | 169.1 m | 180.4 m | SEC (XBRL)· 12 Mar 2026verified |
| Equity | 28.1 m † | 104.2 m † | 123.2 m † | 57.0 m † | 3.6 m † | -15.7 m † | SEC (XBRL)· 12 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 508.0 k | -32.7 m | -61.8 m | -36.3 m | -26.5 m | -24.6 m | SEC (XBRL)· 12 Mar 2026verified |
| Capex | 1.2 m | 2.8 m | 5.5 m | 4.6 m | 3.8 m | 3.2 m | SEC (XBRL)· 12 Mar 2026verified |
| Free cash flow | -686.0 k ≈ | -35.5 m ≈ | -67.3 m ≈ | -40.9 m ≈ | -30.3 m ≈ | -27.8 m ≈ | SEC (XBRL)· 12 Mar 2026derived |
| Investing cash flow | -8.8 m | -12.2 m | -131.6 m | 62.6 m | 46.2 m | -3.1 m | SEC (XBRL)· 12 Mar 2026verified |
| Financing cash flow | 11.9 m | 154.0 m | 92.2 m | -6.8 m | -3.5 m | 11.6 m | SEC (XBRL)· 12 Mar 2026verified |
| Share repurchases | — | 0 | 9.0 m | 1.0 m | 0 | — | SEC (XBRL)· 26 Mar 2025verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 33.3% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 707.3 m USD
Key indicators
Coverage and freshness
Score by group
33% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 0.15 – 0.46 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)0.15 – 0.46 (Mid 0.27)WACC 8.9% · starting FCFF 3.1 m USD · terminal value share of EV 75%The WACC × g sensitivity gives the method's bounds; these are not probabilities.Reverse DCF: no growth between −30% and +40% justifies the price
- Peers: EV/EBITDAunavailable · the base of the ratio is not positive
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -6.2% | 50 (vs peers) | 19% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 25.8% | 100 (on a fixed band) | 25% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -3.4x | 0 (on a fixed band) | 19% |
| Current ratio · Balance sheet | 1.4x | 47 (on a fixed band) | 13% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -0.5% | 0 (on a fixed band) | 25% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet19/100 · 2/3 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality· partial50/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Starling Oncology, Inc. (STLN). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 502.7 m USD in 2025; YoY growth 27.8%; net margin -6.2%.
The estimated value range is 0.15–0.46 USD per share (median of 1 methods, agreement: single method); assumptions are illustrative. Against the central value of 0.27 USD, the price of 6.94 USD leaves a potential of -96.1% (value / price − 1) and a margin of safety of -2,475.8% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 25.8%
What contradicts it
- Interest coverage: -3.4x
- FCF yield: -0.5%
- The price is above the estimated value range
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Services-Offices & Clinics of Doctors of Medicine (SIC 8011) · same industry (4-digit SIC) · compared with 8 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| TDOCTeladoc Health, Inc. | 1.8 bn | — | -11.5% | -6.3% | −1.5% | +28% / −47% |
| STLNStarling Oncology, Inc. | 707.3 m | — | — | -6.2% | +27.8% | +64% / +244% |
| SBCSBC Medical Group Holdings Incorporated | 547.1 m | 11.4 | 19.3% | 28.0% | −15.5% | +49% / −51% |
| CCMConcord Medical Services Holdings Ltd | 481.9 m | — | — | -20.2% | +25.2% | −4% / −63% |
| AIRSAirSculpt Technologies, Inc. | 122.6 m | — | -12.0% | -7.8% | −15.8% | −52% / −66% |
| LFMDLifeMD, Inc. | 118.1 m | — | 6.5% | 0.1% | +25.3% | −36% / −68% |
| BMGLBasel Medical Group Ltd | 8.2 m | — | -169.7% | -94.0% | unavailable | −64% / unavailable |
| AUNAAuna S.A. | — | — | 7.5% | 2.5% | +13.2% | 0% / unavailable |
| HIMSHims & Hers Health, Inc. | 0 | — | -32.0% | -5.5% | +59.0% | −33% / +200% |
1- and 3-year price returns: for STLN from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Starling Oncology (formerly The Oncology Institute) runs community oncology clinics but increasingly earns its revenue from value-based contracts, in which it takes on the cost risk of care for patient populations. Revenue rose 34.6% in the second quarter of 2026 3, and the company raised its 2026 guidance 3, which makes its model closely watched by investors.
SWOT
Strengths
- The value-based contract model provides recurring and predictable revenue through fixed monthly payments per member 1.
- The community clinic network and the large managed patient population give the company a solid position in payor negotiations 12.
- Second quarter 2026 results and the raised guidance indicate operating momentum 3.
Weaknesses
- The company has reported net losses in recent years, and sustainable profitability is not yet demonstrated 13.
- Specialty pharmacy, the fastest-growing segment, carries lower margins than clinical services 1.
- Reliance on a limited number of payors and on reimbursement makes revenue sensitive to their decisions 1.
Opportunities
- Expansion of delegated contracts into new states and the California exclusivity could add capitated revenue 3.
- The shift toward chronic cancer care could increase demand for community oncology services 2.
- Launch of the provider portal could strengthen adherence to clinical pathways across the network 3.
Risks
- Cost estimation riskhigh
In capitation contracts the company bears the risk that costs exceed its payment, and wrong estimates can make contracts unprofitable 1.
- Payor dependencehigh
A significant part of revenue comes from a few payors and pharmacy benefit managers, which could decide to exclude the clinics from their networks 1.
- Regulation and health reformmedium
The company states it cannot predict the effect of health care reform or changes in government programs on its business 1.
- Rapid growth and integrationmedium
Fast expansion of the network and staff could strain management systems and affect the quality of care 1.
- Technology and data riskmedium
Reliance on information systems and third-party vendors exposes the company to outages, security breaches or data loss 12.
Investment thesis
What would need to be true (bull case)
- If capitated revenue grows after the new contracts in Nevada, Oregon and California, the company could turn revenue growth into steadier operating profit 3.
- The high share of value-based contracts and a population of over two million patients offer a base that could support long-term growth 12.
- If adjusted EBITDA stays positive, the company could show that its delegation model is financially sustainable 3.
What would break the thesis
- If payors or regulations cut rates, margins on capitation contracts could fall quickly 1.
- Growth in lower-margin specialty pharmacy could dilute overall profitability if its share keeps rising 1.
- The company has reported net losses in recent periods, and durable profit could lag if expansion costs rise faster than revenue 13.
What to watch
- Third quarter 2026 results and whether adjusted EBITDA meets the third quarter outlookQ3 2026
- Launch of the Starling Nexus provider portal and its effect on network adherenceQ3 2026
- Share of revenue from capitation and the direct cost margin on value-based contractsnext 10-K
- Changes in payor contracts in California and new states, including the rates applied2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Founded in 2007, the company serves adult and senior oncology patients through community clinics run by physician-owned professional corporations, known as PCs. Its central model is capitation contracts and full delegation of care from a payor, which shift risk and treatment coordination to the company. Besides fee-for-service care, it operates specialty pharmacy and clinical trial activities 1.
Value-based contracts are a large share of revenue: in 2025 more than 46% of revenue came from patients covered by such contracts 1. Capitation is paid monthly per member, and profit depends on the gap between that fixed payment and the actual cost of care. The company describes this structure as a way to reduce wasteful treatment and costs for payors and patients 1.
Since 2025 the company has extended its network through full delegation, in which it also performs functions typical of insurers, such as utilization management and claims adjudication, both in its own clinics and in an independent provider network 1. This model allows reach to populations not served directly in company clinics 1.
Market context
The company operates in 17 markets across five states, with 65 clinics owned by affiliated PCs and 81 independently owned clinics contracted with its managed services organization 1. As of June 30, 2026, it managed a population of about 2.1 million patients under value-based agreements 2. The community oncology market is under pressure from rising treatment costs, which makes the company's model relevant to payors 1.
The company links demand to the shift of cancer care toward chronic management rather than acute episodes, which increases the need for high-quality community care 2. Expansion beyond Florida into Nevada and Oregon shows the delegation model is also growing 3. Contracts however depend on payor decisions, which can change or end the relationship 1.
Trends
Competitive position
The company says it faces competition from other healthcare service providers that pursue the same payor relationships and the same physicians and clinical staff 1. Some competitors have greater resources, and consolidation in the industry may raise the cost of winning contracts 1.
The company also names large payor-affiliated networks, including Medicare Advantage organizations, which shows that market position is decided in negotiated contracts 1. A stated advantage is that independent providers can access managed populations without building the required infrastructure themselves 1.
- Anthem
Insurance group named in the source as part of the payor network with which the company holds value-based contracts 1.
- CareMore Health
Medicare Advantage provider named in the source as a contractual partner of the company 1.
- Heritage Provider Network
Provider network named in the source as a payor in value-based contracts 1.
- Optum Care
Care division of a healthcare services group, named as a value-based contract partner 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report02 Sept 2026Departure or appointment of officers
- Current report21 Aug 2026Material agreement · Creation of a direct financial obligation · Financial statements and exhibits
- Quarterly report06 Aug 2026
- Current report06 Aug 2026Results of operations · Financial statements and exhibits
- Current report03 Aug 2026Amendments to articles or bylaws · Regulation FD disclosure · Financial statements and exhibits
- Current report07 Jul 2026Material agreement · Creation of a direct financial obligation · Item 3.02 · Regulation FD disclosure · Financial statements and exhibits
- Current report18 Jun 2026Shareholder vote
- Current report22 May 2026Material cybersecurity incident · Financial statements and exhibits
- Current report07 May 2026Results of operations · Financial statements and exhibits
- Quarterly report07 May 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Starling Oncology, Inc. · 12 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Starling Oncology, Inc. · 06 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Starling Oncology, Inc. · 06 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.